公司资料
Genenta Science 股价、新闻与催化剂
- 股票代码:
- GNTA
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- Italy and listed in the U
股票表现
1.26 USD (+5.88%)
收盘价
最后更新: 2026年8月21日
51.9M USD
市值
股价为何变动
As of Aug 21, 2026, GNTA closed up 5.88% at $1.26. No new same-company headline was identified in the current news window.
公司概览
业务概览
Genenta Science is a cell-therapy company focused on engineered myeloid cells and cancer immunotherapy. Its platform aims to create a new class of cellular medicine for oncology.
所在地与行业分类
Headquartered in Italy and listed in the U.S. as an ADR, Genenta has a global cell-therapy profile.
商业模式特征
The company depends on platform validation, clinical data, and the ability to turn engineered-cell science into oncology value.
生物医药行业定位
Genenta is a high-catalyst cell-therapy name whose stock reacts to translational and clinical milestones.
未来催化剂
- Genenta’s catalysts are its onco-immunology platform and any data that show the hematology / solid-tumor approach can still advance. The company remains early and data-dependent.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。